Home|Journals|Articles by Year|Audio Abstracts


Ulutas Med J. 2022; 8(3): 100-109

Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Shao-Huan Lan, Chien-Ming Chao, Shen-Peng Chang, Li-Chin Lu, Tzu-Liang Hsu.

Cited by 0 Articles

This meta-analysis assessed the efficacy and safety of iclaprim compared with those of vancomycin in the treatment of acute bacterial skin and skin structure infection (ABSSSI). Only randomized controlled trials (RCTs) comparing the effect of iclaprim with vancomycin on adult patients with ABSSSIs were included. A total of 3 RCTs involving 1260 adult patients with ABSSSIs were enrolled. Iclaprim had a non-inferior clinical response rate compared with vancomycin. Similar trend was observed in the following subgroups: major cutaneous abscesses, cellulitis/erysipelas, wound infections, MRSA, MSSA, Streptococcus pyogenes infections. Finally, no differences were observed between iclaprim and vancomycin regarding the risks of any AE, drug-related AE, severe AE, discontinuation of study drug due to AE, and mortality. In conclusion, iclaprim exhibits non-inferior efficacy compared with vancomycin in the treatment of ABSSSI. Additionally, iclaprim was generally as well tolerated as vancomycin.

Key words: Iclaprim, vancomycin, acute bacterial skin and skin structure infection

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.